Your Source for Venture Capital and Private Equity Financings

Massinvestor/VC News Daily

VC-funded Company:

XDx, Inc.
3260 Bayshore Boulevard
Brisbane, CA 94005
Phone: 415-287-2300

XDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMapĀ® Molecular Expression Testing, an FDA- cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. AlloMap is marketed directly by XDx in the United States and has received marketing authorization in the European Union. Some of the AlloMap technology may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system, and XDx is currently developing a lupus flare predictor test in collaboration with LabCorp. XDx's non-invasive technology offers the potential to decrease healthcare costs and improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

Key Contact
Jean Viret
Funding Events

09/13/12 $15,000,000 Growth Oxford Finance
Silicon Valley Bank